|
 Samaritan
Pharmaceuticals Inc., a developer of innovative drugs, is
pleased to announce it has filed a patent application to protect
SP-04 as a new and novel compound to defend and protect the
body against exposure to bioterrorism attacks of nerve gas
agents.
Chemical weapons
have been used in wars since the early 1900s. Of the thousands
of highly poisonous chemicals, experts believe that terrorists
will choose to use nerve agents because of their toxicity.
In modern war, protecting soldiers against any kind of threat
and preserving their ability to fight has become a major concern
of armies, as they have to face new deadly threats on, and
off, the battlefield.
Nerve agents attack
the nervous system of the human body. Generally, nerve agents
function by interrupting the breakdown of the neurotransmitters
that signal muscles to contract, preventing them from relaxing.
Dr. Greeson, CEO
of Samaritan Pharmaceuticals stated, ``Unprotected contact
with nerve gas leads to certain death if appropriate and effective
treatment is not administered very quickly. Preclinical data
has demonstrated SP-04's unique ability to act on various
neural receptor systems, and at the same time, increase the
antioxidant defense of the body against nerve gas. This data
suggests SP-04 as a novel and improved antidote against nerve
gas agents which necessitated the filing of a patent application
to protect its claims.''
Samaritan Pharmaceuticals:
``We LIV....to Save Lives.''
Samaritan is a
small-cap Biotech, driven to discover, develop and commercialize
innovative therapeutics for AIDS, Alzheimer's, Cancer and
Heart disease patients. Look at http://www.samaritanpharma.com.
Please register on Website so we can notify you of upcoming
conference calls, news and events.
The company disclaims
any information that is created by an outside party and endorses
only information that is communicated by its press releases,
filings and Website. This news release contains forward-looking
statements that reflect management's current beliefs about
the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development,
there are significant risks and uncertainties in the process
of development and regulatory review. There are no guarantees
that products will prove to be commercially successful. For
additional information about the factors that affect the company's
business, please read the company's latest Form 10-K/A filed
November 2, 2006. The company undertakes no duty to update
forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan
Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
|
